Hepatitis C Treatment Checklists

Prior to Treatment

Labs:
- Immediately prior: 
  - Pregnancy test (if applicable)
  - Uric Acid (only if ribavirin to be given)
- Within 3 months: 
  - CBC (without diff)
  - HBV DNA (if HBcAb+)
  - HCV RNA
  - Hepatic Function Panel and eGFR
  - PT/INR
- Within 6 months: 
  - Serum fibrosis test (FibroTest-Quest or Fibrosure-LabCorp) or FibroScan
  - AFP
- Within 1 year: 
  - Vitamin D 25OH (consider and treat if deficient)
  - Genotype
  - HIV screening
  - A1C or Fasting Glucose
- Once: 
  - Hepatitis B core antibody & surface antigen
  - NS5a RAS (If failed prior DAA treatment or if cirrhotic genotype 3 & treating with Epclusa)

Miscellaneous:
- Hepatitis A vaccine status (If unknown: draw HAV antibody total IgG)
- Hepatitis B vaccine status (If unknown: draw HBsAg & HBsAb)
- Review drug-drug interactions
- PHQ-9 baseline
- AUDIT-C
- Counsel about pregnancy prevention (ethinyl estradiol not recommended with Mavyret)
- Review & sign Treatment Readiness Attestation
- Review medication-specific Information Packet at Treatment Start

Monitoring During Treatment

- If taking ribavirin, see footnote below.
- Instruct patients taking diabetes meds to monitor for hypoglycemia
- Inform patients taking warfarin of potential need to change dose and monitor INR for sub-therapeutic anticoagulation

Week 4
- HCV RNA (consider if concern for medication adherence)
- LFTs (as clinically indicated)
- Pregnancy test
- HBV DNA

Weeks 8, 12, 16, 20, & 24 (as clinically indicated)
- LFTs (as clinically indicated)
- Pregnancy test
- HBV DNA

1- Hep B: If cAb+ & HBV DNA detected pre-treatment OR if Hep B carrier (sAg+) OR seroconverted carrier, check HBV DNA monthly during treatment & 3 months after treatment. If HBV DNA negative pre-treatment & not a carrier, check again only at end of treatment.
2- Child-Pugh Calculator: [https://www.hepatitis.uw.edu/page/clinical-calculators/ctp](https://www.hepatitis.uw.edu/page/clinical-calculators/ctp)
   - If score >6 (Child-Pugh B or C), do not treat with Mavyret™, Zepatier™, or Vosevi® and consult Liver Disease Specialist.
3- If treatment includes ribavirin, additional monitoring of CBC, CMP is recommended at weeks 2, 4 and monthly throughout treatment and adjustment to ribavirin dose if GFR <50 or anemic. Consult Liver Disease specialist if patient is prescribed ribavirin.

ANTHC LDHP - Outside ASU- 02/06/2020
Hepatitis C Treatment Checklists

**Monitoring After Treatment:**

12 weeks after last dose:
- HCV RNA (to test for cure)
- AFP (if advanced fibrosis or cirrhosis and more than 6 months since last result)
- HBV DNA

6 months post-treatment:
- If Advanced Fibrosis or Cirrhosis prior to treatment continue AFP & RUQ q 6 months to screen for hepatocellular carcinoma (HCC)

1 year post-treatment:
- Zero to minimal scarring (F0-F2): yearly CBC & LFTs as clinically indicated
- Advanced Fibrosis (F3): RUQ US & AFP q 6 months; yearly CBC, LFTs, & AFPs
  - Liver Field Clinic appointment and FibroScan every 2 years. FibroScan to be done in Field Clinic.
- Cirrhosis (F4): RUQ US & AFP q 6 months; yearly CBC, CMP, AFP, PT/INR
  - Yearly Liver Field Clinic appointment. FibroScan to be done at discretion of provider.

---

1- Hep B: If cAb+ & HBV DNA detected pre-treatment OR if Hep B carrier (sAg+) OR seroconverted carrier, check HBV DNA monthly during treatment & 3 months after treatment. If HBV DNA negative pre-treatment & not a carrier, check again only at end of treatment.

2- Child-Pugh Calculator: [https://www.hepatitisc.uw.edu/page/clinical-calculators/ctp](https://www.hepatitisc.uw.edu/page/clinical-calculators/ctp)
If score >6 (Child-Pugh B or C), do not treat with Mavyret™, Zepatier™, or Vosevi® and consult Liver Disease Specialist.

3- If treatment includes ribavirin, additional monitoring of CBC, CMP is recommended at weeks 2, 4 and monthly throughout treatment and adjustment to ribavirin dose if GFR <50 or anemic. Consult Liver Disease specialist if patient is prescribed ribavirin.